Through the 90-day period concluding January 10, 2026, Black Diamond Therapeutics's top three insider stakeholders include Director Ali Behbahani (4.54Mn shares), TenPercentOwner Venture Capital Vi, L.P. Versant (3.73Mn shares), Director Capital Management, L.P. Ra (3.21Mn shares).
| Holder | Position | Shares | Report Date |
|---|---|---|---|
| Ali Behbahani | 4,535,406 | 15 Dec, 2025 | |
| Venture Capital Vi, L.P. Versant | 3,726,341 | 30 Aug, 2024 | |
| Capital Management, L.P. Ra | 3,213,828 | 07 Jul, 2023 | |
| Growth N V Biotech | 2,733,547 | 20 Mar, 2025 | |
| Rajeev M. Shah | 2,277,978 | 21 May, 2021 | |
| David M. Epstein | See Remarks | 671,423 | 28 Jun, 2023 |
| Elizabeth Buck | Chief Scientific Officer | 170,192 | 31 Jan, 2025 |
| Fang Ni | See Remarks | 125,389 | 23 Dec, 2022 |
| Mark A. Velleca | President & Ceo | 121,522 | 31 Jan, 2025 |
| Erika Jones | See Remarks | 85,150 | 31 Jan, 2025 |
| Brent Hatzis-Schoch | See Remarks | 83,400 | 31 Jan, 2025 |
| Sergey Yurasov | Chief Medical Officer | 75,000 | 31 Jan, 2025 |
| Robert Alexander Ingram | 42,854 | 19 Dec, 2022 | |
| Wendy L Dixon | 38,054 | 03 Apr, 2024 | |
| Prakash Raman | 31,027 | 15 Dec, 2025 | |
| Shannon Campbell | 8,865 | 16 Dec, 2024 | |
| Christopher D. Roberts | Chief Scientific Officer | 3,200 | 05 May, 2021 |
* Please note that the shares above only reflect shares from the fund portfolio and the institutional portfolio. Shares from the personal portfolio are excluded from this Institutional Ownership Page. See these insiders' latest transactions here on Insider Page.
| Transaction Date | Insider Name | Security Class | Transaction Type | Shares Traded | Price | Shares Remaining | Ownership | Code |
|---|---|---|---|---|---|---|---|---|
| 12 Dec, 2025 | Ali Behbahani | Common Stock | A | 5,208 | $2.76 | 86,649 | D | A |
| 12 Dec, 2025 | Prakash Raman | Common Stock | A | 4,665 | $2.76 | 31,027 | D | A |
| 19 Sep, 2025 | Ali Behbahani | Common Stock | A | 4,291 | $3.35 | 81,441 | D | A |
| 19 Sep, 2025 | Prakash Raman | Common Stock | A | 3,843 | $3.35 | 26,362 | D | A |
| 20 Jun, 2025 | Ali Behbahani | Common Stock | A | 6,170 | $2.33 | 77,150 | D | A |
| 20 Jun, 2025 | Prakash Raman | Common Stock | A | 5,526 | $2.33 | 22,519 | D | A |
| 21 Mar, 2025 | Ali Behbahani | Common Stock | A | 7,646 | $1.88 | 70,980 | D | A |
| 21 Mar, 2025 | Prakash Raman | Common Stock | A | 6,848 | $1.88 | 16,993 | D | A |
| 19 Mar, 2025 | Growth N V Biotech | - | - | 2,733,547 | D | |||
| 19 Mar, 2025 | Growth N V Biotech | Common Stock | D | 2,000,000 | $2.00 | 4,217,839 | D | S |
| 19 Mar, 2025 | Growth N V Biotech | Common Stock | D | 500,000 | $2.12 | 2,733,547 | D | S |
| 19 Mar, 2025 | Growth N V Biotech | Common Stock | D | 1,000,000 | $2.07 | 7,517,839 | D | S |
| 19 Mar, 2025 | Growth N V Biotech | Common Stock | D | 584,292 | $1.95 | 3,233,547 | D | S |
| 19 Mar, 2025 | Growth N V Biotech | Common Stock | D | 1,000,000 | $2.31 | 6,217,839 | D | S |
| 19 Mar, 2025 | Growth N V Biotech | - | - | 7,517,839 | D | |||
| 19 Mar, 2025 | Growth N V Biotech | - | - | 3,817,839 | D | |||
| 19 Mar, 2025 | Growth N V Biotech | Common Stock | D | 400,000 | $2.09 | 3,817,839 | D | S |
| 19 Mar, 2025 | Growth N V Biotech | - | - | 7,217,839 | D | |||
| 19 Mar, 2025 | Growth N V Biotech | Common Stock | D | 300,000 | $1.94 | 7,217,839 | D | S |
| 19 Mar, 2025 | Growth N V Biotech | - | - | 6,217,839 | D |